Rapid, Multiplexed, Idealized Antiepileptic Drug Monitoring

Information

  • Research Project
  • 10080343
  • ApplicationId
    10080343
  • Core Project Number
    R43NS119024
  • Full Project Number
    1R43NS119024-01
  • Serial Number
    119024
  • FOA Number
    PA-19-272
  • Sub Project Id
  • Project Start Date
    9/1/2020 - 4 years ago
  • Project End Date
    8/31/2021 - 3 years ago
  • Program Officer Name
    CAPORELLO, EMILY LAURA
  • Budget Start Date
    9/1/2020 - 4 years ago
  • Budget End Date
    8/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/25/2020 - 4 years ago

Rapid, Multiplexed, Idealized Antiepileptic Drug Monitoring

Project Summary Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology and clinical chemistry focused on the measurement of drug concentrations, typically in serum or plasma. Quantifying a drug concentration in the body enables a clinician to tailor/optimize prescribed drug dosages to the individual patient, based on establishing and understanding the associated pharmacokinetic and pharmacodynamic relationships of drug metabolism, which can vary drastically between patients. Thus, TDM is critical toward personalizing patient treatment plans and enabling precision medicine for improved patient care and outcomes. However, there is currently no simple, rapid (<15 min), easy-to-use, and inexpensive device that can accurately measure drug levels from a given sample. In response to this technology gap, during this program, Electronic BioSciences (EBS), in collaboration with a highly interdisciplinary team of field experts, will develop a truly unique, enabling, and state-of-the-art TDM technology that overcomes the known target characterization problems that have plagued the biosensor/immunoassay field for years. During this project, EBS will be focusing specifically on antiepileptic drug monitoring, a subset of TDM that has an urgent and pressing need for improved characterization methods, along with a significant commercial potential for the proposed technology once it is developed. However, it should be noted that the technology and associated methodology developed during this program will be transferable to other TDM applications, including but not limited to antibiotics, immunosuppressants, antipsychotics, etc.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    258590
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:258590\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ELECTRONIC BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    129852864
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921214206
  • Organization District
    UNITED STATES